# Indivior PLC (INDV) Stock Analysis: Assessing the 19.7% Potential Upside for Investors

- Link: https://www.directorstalkinterviews.com/indivior-plc-indv-stock-analysis-assessing-the-19-7-potential-upside-for-investors/4121210887
- Published: 2025-08-05T10:40:55+01:00
- Author: Madison Wilson

Indivior PLC (INDV), trading on the U.S. markets, is a key player in the healthcare
sector, specifically within the niche of drug manufacturers specializing in both
specialty and generic products. With a market capitalization of $2.65 billion, the
company has cemented its position as a significant entity in the treatment of opioid
dependence, a pressing issue that continues to garner global attention.

Currently priced at $21.22, Indivior’s stock has experienced a notable upward trajectory,
hitting the top end of its 52-week range from $7.46 to $21.22. This price movement
underscores the company’s robust growth and investor confidence, particularly as
it edges closer to the high end of its target price range, which analysts have set
between $19.00 and $30.00. The average target price of $25.40 suggests a potential
upside of approximately 19.7%, presenting an attractive proposition for potential
investors.

Despite the absence of a trailing P/E ratio, Indivior’s forward P/E is pegged at
11.88, indicating favorable growth expectations relative to its current earnings.
The company’s earnings per share (EPS) stands at $0.82, further affirming its profitability
and capacity for sustainable growth. While some valuation metrics such as PEG ratio
and Price/Book are unavailable, Indivior’s operational health is reflected in its
substantial free cash flow of $255.25 million, a solid indicator of financial flexibility
and potential for reinvestment into product development and expansion.

Indivior’s revenue growth, albeit modest at 1.00%, is complemented by a strategic
focus on expanding its product portfolio. Its core marketed products, including 
SUBLOCADE and SUBOXONE, are well-regarded in the treatment of opioid use disorder(
OUD). Additionally, the company is innovating with products like the OPVEE nasal
spray for opioid overdose reversal, and the promising INDV-2000 and INDV-6001 in
collaboration with Alar Pharmaceuticals Inc., which are advancing through clinical
trials.

The company does not currently offer a dividend, maintaining a payout ratio of 0.00%.
This strategy, while not appealing to income-focused investors, allows Indivior 
to reinvest earnings into growth initiatives and R&D activities, crucial for maintaining
its competitive edge and addressing the evolving needs of the healthcare market.

Indivior’s technical indicators provide further insights into its stock performance.
The 50-day moving average of $14.89 and the 200-day moving average of $11.58 suggest
a strong upward momentum, bolstered by a relative strength index (RSI) of 35.35,
indicating the stock is not overbought. The MACD of 1.49, above the signal line 
of 1.05, reinforces the bullish sentiment surrounding Indivior’s stock.

With six buy ratings and no holds or sells, analyst sentiment remains overwhelmingly
positive. This consensus reflects confidence in Indivior’s strategic direction and
its ability to leverage its expertise in tackling substance use disorders. As the
company continues to innovate and expand its market reach, investors looking for
growth opportunities in the healthcare sector may find Indivior PLC a compelling
addition to their portfolios.

Share on: